C

CytoMed Therapeutics Ltd
NASDAQ:GDTC

Watchlist Manager
CytoMed Therapeutics Ltd
NASDAQ:GDTC
Watchlist
Price: 1.53 USD -0.65% Market Closed
Market Cap: 17.9m USD

Intrinsic Value

The intrinsic value of one GDTC stock under the Base Case scenario is 0.12 USD. Compared to the current market price of 1.53 USD, CytoMed Therapeutics Ltd is Overvalued by 92%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GDTC Intrinsic Value
0.12 USD
Overvaluation 92%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation History
CytoMed Therapeutics Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about GDTC?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is GDTC valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for CytoMed Therapeutics Ltd.

Explain Valuation
Compare GDTC to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about GDTC?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
CytoMed Therapeutics Ltd

Balance Sheet Decomposition
CytoMed Therapeutics Ltd

Current Assets 4.1m
Cash & Short-Term Investments 2.9m
Receivables 172k
Other Current Assets 1.1m
Non-Current Assets 4.3m
Long-Term Investments 228.6k
PP&E 3.5m
Intangibles 72.6k
Other Non-Current Assets 499.9k
Current Liabilities 703.1k
Accounts Payable 82.7k
Accrued Liabilities 264k
Other Current Liabilities 356.4k
Non-Current Liabilities 507.4k
Long-Term Debt 431.8k
Other Non-Current Liabilities 75.6k
Efficiency

Free Cash Flow Analysis
CytoMed Therapeutics Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
CytoMed Therapeutics Ltd

Revenue
225.4k SGD
Operating Expenses
-3.2m SGD
Operating Income
-2.9m SGD
Other Expenses
-744.9k SGD
Net Income
-3.7m SGD
Fundamental Scores

GDTC Profitability Score
Profitability Due Diligence

CytoMed Therapeutics Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

ROE is Increasing
Low 3Y Average Gross Margin
Low Gross Margin
Declining ROIC
19/100
Profitability
Score

CytoMed Therapeutics Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

GDTC Solvency Score
Solvency Due Diligence

CytoMed Therapeutics Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

CytoMed Therapeutics Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GDTC Price Targets Summary
CytoMed Therapeutics Ltd

There are no price targets for GDTC.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

CytoMed Therapeutics Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for GDTC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one GDTC stock?

The intrinsic value of one GDTC stock under the Base Case scenario is 0.12 USD.

Is GDTC stock undervalued or overvalued?

Compared to the current market price of 1.53 USD, CytoMed Therapeutics Ltd is Overvalued by 92%.

Back to Top